GE HealthCare Technologies Forecast, price target & analysts
GE HealthCare Technologies Target price 2025 - Analyst rating & recommendation
GE HealthCare Technologies Classifications & Recommendation:
GE HealthCare Technologies Price Target
| Target Price | $88.74 |
| Price | $71.02 |
| Potential | 24.95% |
| Number of Estimates | 23 |
| 23 Analysts have issued a price target GE HealthCare Technologies 2026 . The average GE HealthCare Technologies target price is $88.74. This is 24.95% higher than the current stock price. The highest price target is $111.30 56.72% , the lowest is $73.73 3.82% . | |
| A rating was issued by 28 analysts: 19 Analysts recommend GE HealthCare Technologies to buy, 9 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the GE HealthCare Technologies stock has an average upside potential 2026 of 24.95% . Most analysts recommend the GE HealthCare Technologies stock at Purchase. |
Sales and Margin forecast 2025, 2026 to 2030
24 Analysts have issued a sales forecast GE HealthCare Technologies 2025 . The average GE HealthCare Technologies sales estimate is $20.9b . This is 3.39% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $21.7b 6.97% , the lowest is $20.0b 1.26% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | $19.7b | 0.61% |
|---|---|---|
| 2025 | $20.9b | 6.41% |
| 2026 | $21.9b | 4.44% |
| 2027 | $22.8b | 4.51% |
| 2028 | $23.6b | 3.30% |
| 2029 | $24.3b | 2.86% |
| 2030 | $24.4b | 0.45% |
17 Analysts have issued an GE HealthCare Technologies EBITDA forecast 2025. The average GE HealthCare Technologies EBITDA estimate is $3.7b . This is 11.42% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $3.9b 18.10% , the lowest is $3.3b 1.21% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | $3.2b | 5.25% |
|---|---|---|
| 2025 | $3.7b | 15.04% |
| 2026 | $4.0b | 7.38% |
| 2027 | $4.2b | 6.37% |
| 2028 | $4.7b | 10.97% |
| 2029 | $4.9b | 5.07% |
EBITDA Margin
| 2024 | 16.29% | 4.61% |
|---|---|---|
| 2025 | 17.61% | 8.09% |
| 2026 | 18.11% | 2.84% |
| 2027 | 18.43% | 1.77% |
| 2028 | 19.80% | 7.43% |
| 2029 | 20.22% | 2.12% |
24 GE HealthCare Technologies Analysts have issued a net profit forecast 2025. The average GE HealthCare Technologies net profit estimate is $2.1b . This is 4.65% lower than the net profit for the last 12 months(TTM). The highest net profit forecast is $2.2b 0.98% , the lowest is $2.0b 9.39% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | $2.0b | 43.90% |
|---|---|---|
| 2025 | $2.1b | 6.07% |
| 2026 | $2.3b | 8.63% |
| 2027 | $2.6b | 11.73% |
| 2028 | $2.8b | 7.65% |
| 2029 | $2.7b | 1.09% |
Net Margin
| 2024 | 10.13% | 43.02% |
|---|---|---|
| 2025 | 10.10% | 0.31% |
| 2026 | 10.50% | 3.96% |
| 2027 | 11.23% | 6.95% |
| 2028 | 11.70% | 4.19% |
| 2029 | 11.25% | 3.85% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2030
24 Analysts have issued a GE HealthCare Technologies forecast for earnings per share. The average GE HealthCare Technologies EPS is $4.64 . This is 4.13% lower than earnings per share in the financial year 2024. The highest EPS forecast is $4.82 0.41% , the lowest is $4.41 8.88% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | $4.34 | 43.23% |
|---|---|---|
| 2025 | $4.64 | 6.91% |
| 2026 | $5.04 | 8.62% |
| 2027 | $5.63 | 11.71% |
| 2028 | $6.06 | 7.64% |
| 2029 | $6.00 | 0.99% |
P/E ratio
| Current | 14.59 | 34.85% |
|---|---|---|
| 2025 | 15.22 | 4.30% |
| 2026 | 14.01 | 7.95% |
| 2027 | 12.54 | 10.49% |
| 2028 | 11.65 | 7.10% |
| 2029 | 11.78 | 1.12% |
Based on analysts' sales estimates for 2025, the GE HealthCare Technologies stock is valued at an EV/Sales of 1.84 and an P/S ratio of 1.54 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 1.90 | 15.93% |
|---|---|---|
| 2025 | 1.84 | 3.21% |
| 2026 | 1.76 | 4.26% |
| 2027 | 1.68 | 4.32% |
| 2028 | 1.63 | 3.20% |
| 2029 | 1.59 | 2.78% |
| 2030 | 1.58 | 0.45% |
P/S ratio
| Current | 1.59 | 16.80% |
|---|---|---|
| 2025 | 1.54 | 3.28% |
| 2026 | 1.47 | 4.25% |
| 2027 | 1.41 | 4.32% |
| 2028 | 1.36 | 3.20% |
| 2029 | 1.33 | 2.78% |
| 2030 | 1.32 | 0.45% |
GE HealthCare Technologies...
Current GE HealthCare Technologies Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Evercore ISI Group |
Outperform
➜
Outperform
|
Unchanged | Oct 30 2025 |
| Morgan Stanley |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Oct 30 2025 |
| Wells Fargo |
Overweight
➜
Overweight
|
Unchanged | Oct 30 2025 |
| Barclays |
➜
Equal-Weight
|
Initiated | Oct 13 2025 |
| BTIG |
Buy
➜
Buy
|
Unchanged | Oct 13 2025 |
| Citigroup |
Buy
➜
Neutral
|
Downgrade | Oct 07 2025 |
| Morgan Stanley |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Jul 31 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
Evercore ISI Group:
Outperform
➜
Outperform
|
Oct 30 2025 |
|
Unchanged
Morgan Stanley:
Equal-Weight
➜
Equal-Weight
|
Oct 30 2025 |
|
Unchanged
Wells Fargo:
Overweight
➜
Overweight
|
Oct 30 2025 |
|
Initiated
Barclays:
➜
Equal-Weight
|
Oct 13 2025 |
|
Unchanged
BTIG:
Buy
➜
Buy
|
Oct 13 2025 |
|
Downgrade
Citigroup:
Buy
➜
Neutral
|
Oct 07 2025 |
|
Unchanged
Morgan Stanley:
Equal-Weight
➜
Equal-Weight
|
Jul 31 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
